 Source: Natali_ MisShutterStock.com Beam Therapeutics NASDAQ: BEAM stock is slipping on Monday after the U.S. Food and Drug Administration FDA placed a clinical hold on one of its drugs. According to a press release from the company, the FDA has put a hold on the Investigational New Drug IND application for BEAM-201. 